tisagenlecleucel
Showing 1 - 6 of 6
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)
Terminated
- Diffuse Large B-cell Lymphoma
- Tisagenlecleucel
- Ibrutinib
-
Tampa, Florida
- +1 more
Jan 27, 2023
Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint
Recruiting
- Refractory Diffuse Large B-cell Lymphoma
- +4 more
- Tisagenlecleucel
-
Duarte, California
- +2 more
Aug 9, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel, Blinatumomab, Inotuzumab)
Withdrawn
- Acute Lymphoblastic Leukemia
- Tisagenlecleucel
- +2 more
- (no location specified)
Jul 7, 2020
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- Tisagenlecleucel
- Lymphodepleting chemotherapy
-
San Francisco, California
- +25 more
Jan 27, 2023